Nkarta, Inc. filings document the regulatory record of a clinical-stage biotechnology company advancing engineered NK cell therapies for autoimmune disease. Recent 8-K reports disclose quarterly and annual financial results, corporate highlights, and clinical-program references for NKX019 and the Ntrust studies.
The company’s proxy materials cover annual meeting governance, director elections, auditor ratification, executive compensation votes, and stockholder voting mechanics. Other filings describe capital-raising infrastructure, including a Form S-3 registration statement and an at-the-market sales agreement for common stock, as well as emerging growth company reporting status and related Exchange Act disclosures.
Nkarta, Inc. reported a Q1 2026 net loss of $27.8 million, slightly improved from $32.0 million a year earlier, as it advances engineered NK cell therapies for autoimmune diseases. Research and development expenses were $25.0 million, reflecting continued investment in lead CAR NK candidate NKX019.
General and administrative expenses fell to $5.9 million from $12.4 million, mainly because prior-year severance from a 2025 workforce reduction did not recur. Nkarta ended March 31, 2026 with cash, cash equivalents, restricted cash and investments totaling $266.7 million, and management believes this will fund operations for at least twelve months.
Nkarta, Inc. reported first quarter 2026 results and progress in its NKX019 autoimmune program. The company ended March 31, 2026 with $266.7 million in cash, cash equivalents, restricted cash and marketable securities, and expects this balance to fund its current operating plan into 2029.
For the quarter, research and development expenses were $25.0 million and general and administrative expenses were $5.9 million, with both including non-cash stock-based compensation. Nkarta recorded a net loss of $27.8 million, or $0.37 per share, narrower than the loss in the prior-year period, helped by lower operating expenses and interest income.
Clinically, enrollment continues in the Ntrust-1 and Ntrust-2 trials of NKX019 across multiple autoimmune diseases, with patients receiving a three-dose cycle totaling 12 billion cells. A recent FDA protocol amendment allows outpatient dosing in community settings, re-dosing options, and expansion of Ntrust-2 to include rheumatoid arthritis, with initial clinical data planned for presentation in 2026.
Nkarta, Inc. is asking stockholders to vote at a fully virtual annual meeting on June 10, 2026. Holders of record on April 17, 2026 can participate via webcast and are being asked to elect two Class III directors, Ali Behbahani and Zachary Scheiner, to serve until the 2029 annual meeting.
Stockholders will also vote on ratifying Ernst & Young LLP as auditor for 2026, approving on an advisory basis executive pay, and choosing the frequency of future say‑on‑pay votes, with the Board recommending one year. The proxy details board structure, committee memberships, independence determinations, executive and director pay, 2025 equity grants, severance protections, related‑party transactions, and ownership, including RA Capital–affiliated entities holding about 18.8% of the outstanding shares.
Nkarta, Inc. has filed a prospectus to offer up to $100,000,000 of its common stock in an at-the-market offering through Stifel, Nicolaus & Company, Incorporated pursuant to a Sales Agreement. The prospectus states the offering may occur from time to time at prevailing market prices and that Stifel may act as agent or, if authorized, as principal.
The cover cites a last reported sale price of $2.05 per share on March 24, 2026. The prospectus provides an illustrative post-offering share count of up to 120,070,977 shares assuming sales of 48,780,487 shares at $2.05. It also discloses a base outstanding share count of 71,078,531 as of December 31, 2025 and other outstanding counts shown with different as-of dates in the text.
Nkarta, Inc. entered into a Sales Agreement with Stifel, Nicolaus & Company for an at-the-market stock offering program. The company may sell, at its discretion, shares of common stock having an aggregate offering price of up to $100,000,000 through Stifel as sales agent.
The company will set sale parameters such as size, timing, daily limits and minimum prices, and will pay Stifel a commission of up to 3% of gross proceeds on shares sold. The shares will be issued under Nkarta’s effective Form S-3 registration statement and related at-the-market prospectus supplement filed with the SEC on March 25, 2026.
Nkarta, Inc. filed a shelf registration on Form S-3 to register up to $350,000,000 of securities, including an at-the-market program for up to $100,000,000.
The shelf prospectus describes offers of common stock, preferred stock, debt securities, warrants, rights and units that may be sold separately or together in one or more offerings. The at-the-market sales agreement with Stifel, Nicolaus & Company, Incorporated permits sales of up to $100,000,000 of common stock under an ATM; Stifel may act as agent or principal and may receive up to 3.0% of gross proceeds as compensation. The prospectus discloses 74,290,521 shares of common stock issued and outstanding as of March 18, 2026 (including 3,000,031 shares underlying pre-funded warrants) and notes that specific terms for each offering will be provided in prospectus supplements.
Nkarta, Inc. is a clinical-stage biopharmaceutical company developing allogeneic, off‑the‑shelf engineered NK cell therapies, led by NKX019, a CD19‑targeted CAR NK candidate for B‑cell–mediated autoimmune diseases such as lupus nephritis, primary membranous nephropathy, scleroderma, myositis and ANCA‑associated vasculitis.
NKX019 is in multiple Phase 1 trials (Ntrust‑1, Ntrust‑2) and investigator‑sponsored studies, supported by an internal CAR NK platform, cGMP manufacturing in South San Francisco and an extensive patent estate. The company has no approved products, has incurred significant losses and expects to need additional capital. As of June 30, 2025, equity held by non‑affiliates was valued at approximately $82.6 million, and as of March 18, 2026, there were 71,290,490 common shares outstanding.
Nkarta, Inc. reported fourth quarter and full year 2025 results and highlighted progress in its NKX019 autoimmune program. Cash, cash equivalents, restricted cash and investments totaled $295.1 million as of December 31, 2025, and are expected to fund operations into 2029.
For 2025, Nkarta recorded a net loss of $104.1 million, or $1.41 per share$90.4 million and general and administrative expenses were $31.6 million. Fourth quarter 2025 net loss was $27.4 million, or $0.37 per share.
Clinically, dose escalation for NKX019 advanced to 4 billion cells per dose on days 0, 3 and 7, for a total of 12 billion cells per cycle in the Ntrust-1 and Ntrust-2 autoimmune trials. Initial clinical data from these trials are planned for presentation at a medical conference in 2026.